Nautilus Biotechnology (NAUT) versus competitive financial analysis

Nautilus Biotechnology (NAUT) against its peers Head-to-Head Tackle

Nautilus Biotechnology (NASDAQ: NAUT – Get Rating) is one of 43 publicly traded companies in the “analytical tools” sector, but how does it position itself against its competitors? We will compare Nautilus Biotechnology to similar companies based on the strength of its risk, earnings, dividends, analyst recommendations, valuation, profitability, and institutional ownership.

Analyst recommendations

This is a breakdown of recent assessments and recommendations for Nautilus Biotechnology and its competitors, as provided by MarketBeat.

Sell ​​ratings Keep the ratings Buy ratings Strong purchase ratings Evaluation score
Nautilus Biotechnology 0 2 2 0 2.50
Nautilus Competing biotechnologies 319 1325 1830 57 2.46

Nautilus Biotechnology currently has a consensus price target of $ 8.67, suggesting a potential upside of 105.86%. As a group, the “analytics” companies have a potential upside of 31.44%. Given Nautilus Biotechnology’s stronger consensus rating and possible higher upside, equity analysts clearly believe Nautilus Biotechnology is more favorable than its competitors.

Insider and institutional ownership

47.9% of Nautilus Biotechnology’s shares are owned by institutional investors. Comparatively, 60.0% of the shares of all “analytical instruments” companies are owned by institutional investors. 13.4% of the shares of all “Analytical Tools” companies are owned by corporate insiders. Strong institutional ownership indicates that large fund, endowment and hedge fund managers believe a stock is poised for long-term growth.

Earnings and evaluation

This table compares the gross sales, earnings per share, and valuation of Nautilus Biotechnology and its competitors.

Gross Income Net income Price / earnings ratio
Nautilus Biotechnology N / A – $ 50.31 million -7.39
Nautilus Competing biotechnologies 1.19 billion dollars $ 356.47 million -8.39

Nautilus Biotechnology’s competitors have higher revenue and earnings than Nautilus Biotechnology. Nautilus Biotechnology is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.


This table compares Nautilus Biotechnology and its competitors’ net margins, return on equity and return on equity.

Net margins Return on equity Return on assets
Nautilus Biotechnology N / A -15.57% -14.77%
Nautilus Competing biotechnologies -187.73% 3.44% -10.22%


Competitors from Nautilus Biotechnology beat Nautilus Biotechnology on 8 of the 11 factors compared.

Information on Nautilus biotechnology (Get evaluation)

Nautilus Biotechnology, Inc., a developing life science company, is committed to creating a technology platform to quantify and unlock the complexity of the proteome. Develop Nautilus Platform, a proteomics platform that includes an end-to-end solution consisting of tools, consumables, and software analytics. The company was founded in 2016 and is headquartered in Seattle, Washington.

Receive news and ratings for Nautilus Biotechnology Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Nautilus Biotechnology and related companies with’s FREE daily newsletter.


Leave a Comment

Your email address will not be published.